Cover - Brain |
1 |
ESTRO Course Book |
1 |
Multidisciplinary Management of |
1 |
Brain Tumours |
1 |
4 - 6 October, 2015 |
1 |
Turin, Italy |
1 |
L02_ESTRO 2015 Brain Tumor Imaging_RB |
7 |
Modern Imaging of Brain Tumours |
7 |
Slide Number 2 |
8 |
Slide Number 3 |
9 |
Slide Number 4 |
10 |
Slide Number 5 |
11 |
Slide Number 6 |
12 |
Slide Number 7 |
13 |
Slide Number 8 |
14 |
Slide Number 9 |
15 |
Slide Number 10 |
16 |
Slide Number 11 |
17 |
Slide Number 12 |
18 |
Slide Number 13 |
19 |
Slide Number 14 |
20 |
Slide Number 15 |
21 |
Slide Number 16 |
22 |
Slide Number 17 |
23 |
Slide Number 18 |
24 |
Slide Number 19 |
25 |
Slide Number 20 |
26 |
Slide Number 21 |
27 |
Slide Number 22 |
28 |
Slide Number 23 |
29 |
Slide Number 24 |
30 |
Trans-Cranial Magnetic Stimulation |
31 |
Trans-Cranial Magnetic Stimulation |
32 |
Slide Number 27 |
33 |
Slide Number 28 |
34 |
Slide Number 29 |
35 |
Slide Number 30 |
36 |
Slide Number 31 |
37 |
Slide Number 32 |
38 |
L03_What is new in brain tumor classification PC TP |
39 |
Slide Number 1 |
39 |
Slide Number 2 |
40 |
Brain tumor diagnosis: a challenge step by step |
41 |
Histological Parameters for Grading |
42 |
Slide Number 5 |
43 |
Slide Number 6 |
44 |
Slide Number 7 |
45 |
Slide Number 8 |
46 |
A grade IV glioma is histologically diagnosed in presence of: |
47 |
Brain tumor diagnosis: a challenge step by step |
48 |
Slide Number 11 |
49 |
Slide Number 12 |
50 |
Slide Number 13 |
51 |
Slide Number 14 |
52 |
Slide Number 15 |
53 |
Slide Number 16 |
54 |
Slide Number 17 |
55 |
Neuropathology report should: |
56 |
Brain tumor diagnosis: a challenge step by step |
57 |
Slide Number 20 |
58 |
Slide Number 21 |
59 |
Slide Number 22 |
60 |
Slide Number 23 |
61 |
Brain tumor diagnosis: a challenge step by step |
62 |
Slide Number 25 |
63 |
Slide Number 26 |
64 |
Slide Number 27 |
65 |
Neuropathology report should: |
66 |
L04_Bhangoo_Turin_RB |
67 |
Current Surgical Approaches for Brain Tumours |
67 |
Slide Number 2 |
68 |
Slide Number 3 |
69 |
Volumetric extent of resection studies in High-Grade Glioma |
70 |
Slide Number 5 |
71 |
Slide Number 6 |
72 |
Slide Number 7 |
73 |
Slide Number 8 |
74 |
Cochrane review |
75 |
Slide Number 10 |
76 |
Slide Number 11 |
77 |
Cortical and subcortical mapping strategies |
78 |
Motor mapping |
79 |
EEG Electrodes |
80 |
Cortical Strips – Ecog and Tonic Stimulation |
81 |
Cortical Strip over Upper Limb Representation |
82 |
EMG Outputs - Subcortical |
83 |
EMG Output - Subcortical |
84 |
Cortical and subcortical motor mapping |
85 |
Language mapping |
86 |
Language mapping |
87 |
Slide Number 22 |
88 |
Intraoperative stimulation mapping – cinical relevance |
89 |
Beyond motor and language |
90 |
Slide Number 25 |
91 |
Slide Number 26 |
92 |
Intraoperative use of 5-ALA |
93 |
Slide Number 28 |
94 |
Slide Number 29 |
95 |
Slide Number 30 |
96 |
Slide Number 31 |
97 |
Slide Number 32 |
98 |
Slide Number 33 |
99 |
Slide Number 34 |
100 |
Intra-operative MRI |
101 |
Slide Number 36 |
102 |
Pre-operative planning in ACS view |
103 |
First and second US acquisition |
104 |
Towards end of resection |
105 |
Slide Number 40 |
106 |
Slide Number 41 |
107 |
Slide Number 42 |
108 |
Slide Number 43 |
109 |
Slide Number 44 |
110 |
Slide Number 45 |
111 |
Slide Number 46 |
112 |
Slide Number 47 |
113 |
Slide Number 48 |
114 |
Slide Number 49 |
115 |
Slide Number 50 |
116 |
Slide Number 51 |
117 |
Case III – postop course |
118 |
30 year old male – Left Hemiparesis |
119 |
Immediate Post –Op Scan |
120 |
3 Years Later |
121 |
Slide Number 56 |
122 |
Dendritic-cell immunotherapy (DC-VAX) |
123 |
DC-Vax Production |
124 |
DC-Vax |
125 |
Use the Genomics |
126 |
Genetics |
127 |
Genetics |
128 |
Slide Number 63 |
129 |
Slide Number 64 |
130 |
Slide Number 65 |
131 |
Slide Number 66 |
132 |
Slide Number 67 |
133 |
Slide Number 68 |
134 |
Take-home Message |
135 |
L05_1 brain tumour RT - preparing pt for treatment_MB |
136 |
Slide Number 1 |
136 |
Preparation for radiotherapy |
137 |
Preparation for radiotherapy |
138 |
Preparation for radiotherapy |
139 |
Patient position |
140 |
Patient position |
141 |
Preparation for radiotherapy |
142 |
Preparation for radiotherapy |
143 |
Preparation for radiotherapy |
144 |
Preparation for radiotherapy |
145 |
Preparation for radiotherapy |
146 |
Preparation for radiotherapy |
147 |
Preparation for radiotherapy |
148 |
Preparation for radiotherapy |
149 |
Preparation for radiotherapy |
150 |
Preparation for radiotherapy |
151 |
Preparation for radiotherapy |
152 |
Preparation for radiotherapy |
153 |
Preparation for radiotherapy |
154 |
Preparation for radiotherapy |
155 |
Preparation for radiotherapy |
156 |
Preparation for radiotherapy |
157 |
Principles of plan evaluation |
158 |
Principles of plan evaluation |
159 |
Preparation for radiotherapy |
160 |
Slide Number 26 |
161 |
L06_Wide field irradiation_CM |
162 |
Slide Number 1 |
162 |
Slide Number 2 |
163 |
Radiotherapy technique |
164 |
A complex technique…. |
165 |
That has to be done properly…. |
166 |
A standard CSI technique |
167 |
CSI in 2015: new/improved tools |
168 |
Slide Number 8 |
169 |
Slide Number 9 |
170 |
Slide Number 10 |
171 |
Coverage of the target volume: cribriform plate |
172 |
Coverage of the target volume: cribriform plate |
173 |
Slide Number 13 |
174 |
Slide Number 14 |
175 |
Slide Number 15 |
176 |
Another new problem… extension of subarachnoid space around cranial nerves |
177 |
The lower cranial nerves too… |
178 |
Slide Number 18 |
179 |
Slide Number 19 |
180 |
Coverage of the spine: lateral borders |
181 |
Why is this important? |
182 |
Coverage of the spine: caudal extent of thecal sac |
183 |
Why is this important? |
184 |
Coverage of the spine: caudal extent of thecal sac |
185 |
Slide Number 25 |
186 |
Bottom line… |
187 |
Radiotherapy technique: CSI |
188 |
A standard CSI technique |
189 |
Conventional technique |
190 |
Just some of the issues… |
191 |
Just some of the issues… |
192 |
Evolution of CSI technique |
193 |
Slide Number 33 |
194 |
McGill technique |
195 |
McGill technique: junctions |
196 |
McGill technique: junctions |
197 |
McGill technique: junctions |
198 |
Comparison with other CT-based techniques |
199 |
Slide Number 39 |
200 |
Long-term complications of radiotherapy |
201 |
Slide Number 41 |
202 |
Slide Number 42 |
203 |
Electrons for the spinal axis |
204 |
Slide Number 44 |
205 |
Slide Number 45 |
206 |
Slide Number 46 |
207 |
Slide Number 47 |
208 |
No junctions or field matching |
209 |
Slide Number 49 |
210 |
Protons |
211 |
Slide Number 51 |
212 |
CSI: concluding remarks |
213 |
CSI: concluding remarks |
214 |
Slide Number 54 |
215 |
Slide Number 55 |
216 |
Slide Number 56 |
217 |
Slide Number 57 |
218 |
Slide Number 58 |
219 |
Slide Number 59 |
220 |
Slide Number 60 |
221 |
Slide Number 61 |
222 |
Slide Number 62 |
223 |
Slide Number 63 |
224 |
Slide Number 64 |
225 |
Slide Number 65 |
226 |
Slide Number 66 |
227 |
Slide Number 67 |
228 |
L07_2 RT techniques - localised treatments |
229 |
Slide Number 1 |
229 |
Localised radiotherapy for intracranial tumours |
230 |
Techniques of local radiation delivery |
231 |
Classification of radiotherapy technologies |
232 |
Classification of radiotherapy technologies |
233 |
Slide Number 6 |
234 |
Slide Number 7 |
235 |
Classification of radiotherapy technologies |
236 |
Methods of immobilization |
237 |
Methods of immobilization |
238 |
Methods of immobilization |
239 |
Comparison of immobilisation techniques |
240 |
Comparison of immobilisation techniques |
241 |
Comparison of immobilisation techniques |
242 |
Comparison of immobilisation techniques |
243 |
Classification of radiotherapy technologies |
244 |
Classification of radiotherapy technologies |
245 |
Classification of radiotherapy technologies |
246 |
Deconstructing stereotactic radiotherapy |
247 |
Classification of radiotherapy technologies |
248 |
Classification of radiotherapy technologies |
249 |
Classification of radiotherapy technologies |
250 |
Interfraction motion |
251 |
Intrafraction motion in CK radiosurgery |
252 |
Intrafraction motion in CK radiosurgery |
253 |
Classification of radiotherapy technologies |
254 |
Classification of radiotherapy technologies |
255 |
Radiotherapy of intracranial tumours |
256 |
Radiotherapy of intracranial tumours |
257 |
Radiotherapy of intracranial tumours |
258 |
High grade glioma |
259 |
High grade glioma |
260 |
Craniopharyngioma |
261 |
Craniopharyngioma |
262 |
Localised radiotherapy for CNS tumours |
263 |
Localised radiotherapy for CNS tumours |
264 |
Slide Number 37 |
265 |
Slide Number 38 |
266 |
Slide Number 39 |
267 |
Slide Number 40 |
268 |
Slide Number 41 |
269 |
Slide Number 42 |
270 |
Slide Number 43 |
271 |
Localised radiotherapy for CNS tumours |
272 |
Comparison of conformal fixed field & multiple isocentre techniques |
273 |
Localised radiotherapy for CNS tumours |
274 |
Comparison of conformal radiotherapy techniques |
275 |
Comparison of conformal radiotherapy techniques |
276 |
Comparison of conformal radiotherapy techniques |
277 |
Localised radiotherapy for CNS tumours |
278 |
IMRT for meningioma |
279 |
Slide Number 52 |
280 |
Comparison of conformal radiotherapy techniques |
281 |
Comparison of conformal radiotherapy techniques |
282 |
Comparison of conformal radiotherapy techniques |
283 |
Slide Number 56 |
284 |
Slide Number 57 |
285 |
Slide Number 58 |
286 |
Collimation |
287 |
Collimation |
288 |
Collimation |
289 |
Comparison of conformal radiotherapy techniques |
290 |
Classification of radiotherapy technologies |
291 |
Slide Number 64 |
292 |
L08_Radiation tolerance of the CNS_Damien Charles Weber_Brain tumor ESTRO 2015_150915 |
293 |
Slide Number 1 |
293 |
Why high-dose delivered to the brain? |
294 |
Acute toxicity |
295 |
Alopecia |
296 |
Alopecia |
297 |
Alopecia |
298 |
Late toxicity After Radiotherapy…. |
299 |
Type of Late Toxicity (CNS) |
300 |
Factors affecting toxicity (General) |
301 |
Brain Toxicity |
302 |
Brain Toxicity QUANTEC |
303 |
Brain Toxicity QUANTEC |
304 |
Brain necrosis Introduction |
305 |
Brain necrosis (0) |
306 |
Slide Number 15 |
307 |
Brain necrosis (2) |
308 |
Slide Number 17 |
309 |
Brain necrosis |
310 |
Brainstem tolerance |
311 |
Brainstem tolerance |
312 |
Pituitary |
313 |
Pituitary |
314 |
Pituitary |
315 |
Hearing Loss |
316 |
Hearing Loss |
317 |
Hearing Loss |
318 |
Hearing Loss |
319 |
Visual toxicity |
320 |
Visual toxicity |
321 |
Visual toxicity |
322 |
Visual toxicity |
323 |
Visual toxicity |
324 |
Visual toxicity |
325 |
Memory loss |
326 |
Memory loss |
327 |
Memory loss |
328 |
Memory Loss |
329 |
Memory loss |
330 |
Memory loss |
331 |
Conclusions (late toxicity) |
332 |
Slide Number 41 |
333 |
L09_ESTRO_systemic-therapy-issues-Roth_PR |
334 |
Slide Number 1 |
334 |
Slide Number 2 |
335 |
Slide Number 3 |
336 |
Slide Number 4 |
337 |
Slide Number 5 |
338 |
Slide Number 6 |
339 |
Slide Number 7 |
340 |
Slide Number 8 |
341 |
Slide Number 9 |
342 |
Slide Number 10 |
343 |
Slide Number 11 |
344 |
Slide Number 12 |
345 |
Slide Number 13 |
346 |
Slide Number 14 |
347 |
Slide Number 15 |
348 |
Slide Number 16 |
349 |
PCV |
350 |
What is PCV? |
351 |
What is PCV? |
352 |
PCV toxicities EORTC 26951 vs RTOG 9402 |
353 |
Systemic treatment of brain mets |
354 |
Slide Number 22 |
355 |
Slide Number 23 |
356 |
Slide Number 24 |
357 |
Slide Number 25 |
358 |
Slide Number 26 |
359 |
Slide Number 27 |
360 |
Slide Number 28 |
361 |
Slide Number 29 |
362 |
Slide Number 30 |
363 |
Slide Number 31 |
364 |
Slide Number 32 |
365 |
Slide Number 33 |
366 |
Slide Number 34 |
367 |
Slide Number 35 |
368 |
Slide Number 36 |
369 |
L10_ESTRO Brain Tumour Course systemic novel agents Chalmers 4oct15 |
370 |
Systemic treatment for gliomas:Novel therapies |
370 |
Slide Number 2 |
371 |
Slide Number 3 |
372 |
Slide Number 4 |
373 |
Slide Number 5 |
374 |
EGFR |
375 |
Slide Number 7 |
376 |
Slide Number 8 |
377 |
Slide Number 9 |
378 |
Slide Number 10 |
379 |
Slide Number 11 |
380 |
Slide Number 12 |
381 |
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).2014 ASCO Annual Meeting |
382 |
Slide Number 14 |
383 |
Slide Number 15 |
384 |
Slide Number 16 |
385 |
Slide Number 17 |
386 |
Slide Number 18 |
387 |
Slide Number 19 |
388 |
Slide Number 20 |
389 |
Slide Number 21 |
390 |
Slide Number 22 |
391 |
Slide Number 23 |
392 |
Summary |
393 |
L11_TORINO 2015_ESTRO_QoL issues in Neuro-Oncology_RS |
394 |
QUALITY OF LIFE ISSUES IN NEURO-ONCOLOGY |
394 |
CONFLICT OF INTEREST |
395 |
OUTLINE |
396 |
Slide Number 4 |
397 |
MEASURING HRQoL AND COGNITIVE FUNCTIONS IN BRAIN TUMORS PATIENTS: CRITICAL ISSUES |
398 |
Slide Number 6 |
399 |
Slide Number 7 |
400 |
Slide Number 8 |
401 |
Slide Number 9 |
402 |
Slide Number 10 |
403 |
Slide Number 11 |
404 |
Slide Number 12 |
405 |
Slide Number 13 |
406 |
Slide Number 14 |
407 |
WBRT MAY NEGATIVELY IMPACT HEALTH-RELATED QUALI TY OF LIFE (HRQL) IN BRAIN METASTASIS |
408 |
Results: Global health status / QoL |
410 |
Results: secondary QoL endpoints |
411 |
NEUROCOGNITIVE FUNCTIONING IN ADULT WHO GRADE II GLIOMAS : IMPACT OF OLD AND NEW TREATMENT MODALITIES |
412 |
Slide Number 20 |
413 |
Slide Number 21 |
414 |
IMPACT OF WBRT ON COGNITIVE FUNCTIONS : GENERAL CONCEPTS IN BRAIN METASTASIS |
415 |
WHAT HAVE WE LEARNED FROM CLINICAL TRIALS : EARLY DECLINE AFTER WBRT FOR BRAIN METASTASIS |
416 |
Slide Number 24 |
417 |
Slide Number 25 |
418 |
RATIONALE FOR NEUROPROTECTIVE DRUGS IN ASSOCIATION WITH WBRT |
419 |
Slide Number 27 |
420 |
Slide Number 28 |
421 |
RATIONALE FOR HIPPOCAMPAL AVOIDANCE IN ASSOCIATION WITH WBRT |
422 |
Hippocampal Injury from Cranial RT |
423 |
Slide Number 31 |
424 |
Slide Number 32 |
425 |
RATIONALE FOR NON-STEROIDAL ANTI-INFLAMMATORY THERAPY |
426 |
HOW TO TREAT RADIATION-ASSOCIATED NEUROCOGNITIVE SYMPTOMS ? |
427 |
Slide Number 35 |
428 |
Slide Number 36 |
429 |
RISK OF RADIONECROSIS FOLLOWING SRS TO THE RESECTION CAVITY |
430 |
RISK OF RADIONECROSIS FOLLOWING SRS TO THE RESECTION CAVITY |
431 |
RISKS OF NEUROLOGICAL COMPLICATIONS OTHER THAN RADIONECROSIS FOLLOWING SRS TO THE RESECTION CAVITY |
432 |
Slide Number 40 |
433 |
L12_ESTRO low grade glioma Chalmers 4oct15_AC |
434 |
Management of low grade astrocytoma |
434 |
Slide Number 2 |
435 |
Patients with grade 2 astrocytomas require treatment if: |
436 |
Slide Number 4 |
437 |
Slide Number 5 |
438 |
Slide Number 6 |
439 |
Slide Number 7 |
440 |
Slide Number 8 |
441 |
Slide Number 9 |
442 |
For patients with grade 2 astrocytoma WITHOUT 1p19q codeletion who DO require treatment, I would recommend: |
443 |
For patients with grade 2 astrocytoma WITHOUT 1p19q codeletion who require radiotherapy, I would recommend: |
444 |
Slide Number 12 |
445 |
Slide Number 13 |
446 |
Slide Number 14 |
447 |
L13_ESTRO_Treatment _LOH1p19q_PR |
448 |
Slide Number 1 |
448 |
Slide Number 2 |
449 |
Slide Number 3 |
450 |
Slide Number 4 |
451 |
Slide Number 5 |
452 |
Slide Number 6 |
453 |
Slide Number 7 |
454 |
Slide Number 8 |
455 |
Slide Number 9 |
456 |
Slide Number 10 |
457 |
PCV toxicities EORTC 26951 vs RTOG 9402 |
458 |
Reasons for discontinuation of PCV in EORTC 26951 |
459 |
Slide Number 13 |
460 |
Can we avoid RT and use chemotherapy alone? |
461 |
Time to treatment failure – by therapy |
462 |
Time to treatment failure – by therapy/histology |
463 |
Time to treatment failure – by molecular diagnosis |
464 |
Overall survival – by therapy |
465 |
Overall survival – by molecular diagnosis |
466 |
Efficacy outcomes – by molecular diagnosis/therapy |
467 |
Efficacy outcomes – across trial |
468 |
CODEL trial: initial design |
469 |
CODEL trial: updated design |
470 |
Slide Number 26 |
471 |
And in patients with low-grade gliomas…? |
472 |
And in patients with low-grade gliomas…? |
473 |
Slide Number 30 |
474 |
Slide Number 31 |
475 |
Slide Number 32 |
476 |
Slide Number 33 |
477 |
Slide Number 34 |
478 |
L14_Chalmers high grade astrocytoma ESTRO 5oct15 _AC |
479 |
Management of high grade glioma |
479 |
Prognostic factors |
480 |
Slide Number 3 |
481 |
Slide Number 4 |
482 |
Slide Number 5 |
483 |
Slide Number 6 |
484 |
Slide Number 7 |
485 |
Slide Number 8 |
486 |
The treatment I would recommend for a patient with grade 3 glioma without 1p19q codeletion is: |
487 |
Slide Number 10 |
488 |
Slide Number 11 |
489 |
Slide Number 12 |
490 |
Slide Number 13 |
491 |
Slide Number 14 |
492 |
‘Stupp’ regime |
493 |
Mature data |
494 |
Slide Number 17 |
495 |
Chemoradiation for GBM |
498 |
Slide Number 21 |
499 |
Slide Number 22 |
500 |
Slide Number 23 |
501 |
Slide Number 24 |
502 |
Slide Number 25 |
503 |
Slide Number 26 |
504 |
Slide Number 27 |
505 |
Slide Number 28 |
506 |
Relapsed GBM after RT-TMZ |
507 |
Slide Number 30 |
508 |
Slide Number 31 |
509 |
42 year old patient with MGMT methylated GBM, >90% resection, RT-TMZ. Recurrent, inoperable disease 14 months after completing adjuvant TMZ; PS=1. I would recommend: |
510 |
61 year old patient with MGMT unmethylated GBM, >90% resection, RT-TMZ. Recurrent, inoperable disease 5 months after completing adjuvant TMZ; PS=1. I would recommend: |
511 |
L15_Ependymoma_Damien Charles Weber_Ranj Bhangoo_210915 |
512 |
Slide Number 1 |
512 |
Slide Number 2 |
513 |
Introduction (1) |
514 |
Introduction (2) |
515 |
Slide Number 5 |
516 |
Introduction (3) |
517 |
Outcome |
518 |
EP Prognostic factors |
519 |
Prognostic factors |
520 |
Slide Number 10 |
521 |
EP and chemotherapy |
522 |
EP and chemotherapy |
523 |
EP and chemotherapy |
524 |
EP and chemotherapy |
525 |
Current stratgey |
526 |
Current strategy |
527 |
RT and EP (treatment volume) |
528 |
Slide Number 18 |
529 |
RT and EP (dose) |
530 |
RT and treatment duration |
531 |
RT and treatment duration |
532 |
Slide Number 22 |
533 |
L15_ependymomas_RB |
534 |
Management of ependymomas |
534 |
Slide Number 2 |
535 |
Myxopapillary |
536 |
Slide Number 4 |
537 |
Slide Number 5 |
538 |
Slide Number 6 |
539 |
Paediatric Ependymoma |
540 |
Paediatric Ependymoma |
541 |
Adult Ependymoma |
542 |
Drop Mets in Ependymoma |
543 |
Treatment |
544 |
Slide Number 12 |
545 |
Anatomy of the Brain Stem |
546 |
Anatomy of the Brain Stem |
547 |
Slide Number 15 |
548 |
Slide Number 16 |
549 |
Slide Number 17 |
550 |
Slide Number 18 |
551 |
Neurological Outcome after Surgery |
552 |
Adjuvant Treatment |
553 |
Recurrence |
554 |
Conclusion |
555 |
L16_GCT_UR(very final) |
556 |
Slide Number 1 |
556 |
Slide Number 2 |
557 |
Slide Number 3 |
558 |
Slide Number 4 |
559 |
Slide Number 5 |
560 |
Slide Number 6 |
561 |
Slide Number 7 |
562 |
Slide Number 8 |
563 |
Slide Number 9 |
564 |
Slide Number 10 |
565 |
Slide Number 11 |
566 |
Slide Number 12 |
567 |
Slide Number 13 |
568 |
Slide Number 14 |
569 |
Slide Number 15 |
570 |
CNS GCT: Extent of surgery |
571 |
Primary CNS Germinoma- Pathology |
572 |
CNS GCT: Diagnostic work-up and Staging |
573 |
Slide Number 19 |
574 |
Slide Number 20 |
575 |
Slide Number 21 |
576 |
Germinoma: Management |
577 |
CSI: risk for late toxicities |
578 |
Slide Number 24 |
579 |
Slide Number 25 |
580 |
Slide Number 26 |
581 |
Slide Number 27 |
582 |
Slide Number 28 |
583 |
Slide Number 29 |
584 |
Slide Number 30 |
585 |
Slide Number 31 |
586 |
Slide Number 32 |
587 |
Slide Number 33 |
588 |
Slide Number 34 |
589 |
Slide Number 35 |
590 |
Slide Number 36 |
591 |
Slide Number 37 |
592 |
Slide Number 38 |
593 |
Slide Number 39 |
594 |
Slide Number 40 |
595 |
Slide Number 41 |
596 |
Slide Number 42 |
597 |
Slide Number 43 |
598 |
WVI: definition |
599 |
RT techniques for ventricular system irradiation |
600 |
WVI: concave-shaped target for IMRT |
601 |
Slide Number 47 |
602 |
Slide Number 48 |
603 |
Slide Number 49 |
604 |
Slide Number 50 |
605 |
Primary CNS Secreting GCT’s - Pathology |
606 |
Slide Number 52 |
607 |
Slide Number 53 |
608 |
Slide Number 54 |
609 |
Slide Number 55 |
610 |
Slide Number 56 |
611 |
Slide Number 57 |
612 |
Slide Number 58 |
613 |
Slide Number 59 |
614 |
Slide Number 60 |
615 |
Slide Number 61 |
616 |
Slide Number 62 |
617 |
Slide Number 63 |
618 |
L17_ESTRO_PCNSL_PR |
619 |
Slide Number 1 |
619 |
Slide Number 2 |
620 |
Slide Number 3 |
621 |
Slide Number 4 |
622 |
Slide Number 5 |
623 |
Slide Number 6 |
624 |
Slide Number 7 |
625 |
Slide Number 8 |
626 |
Slide Number 9 |
627 |
Slide Number 10 |
628 |
Slide Number 11 |
629 |
Slide Number 12 |
630 |
Slide Number 13 |
631 |
Slide Number 14 |
632 |
Slide Number 15 |
633 |
Slide Number 16 |
634 |
Slide Number 17 |
635 |
Slide Number 19 |
636 |
Slide Number 20 |
637 |
Slide Number 21 |
638 |
Slide Number 22 |
639 |
Slide Number 23 |
640 |
Slide Number 24 |
641 |
Elderly PCNSL patients: a particular challenge |
642 |
Elderly PCNSL patients in G-PCNSL-SG1 |
643 |
Elderly PCNSL patients in G-PCNSL-SG1 |
644 |
MTX/TMZ vs. MPV-A in elderly patients |
645 |
MTX/TMZ vs. MPV-A in elderly patients |
646 |
MTX-based therapy in elderly patients |
647 |
Slide Number 31 |
648 |
L18_HGG in children_DH 2015 Version |
649 |
Slide Number 1 |
649 |
Biopsy of brainstem glioma is standard Ix! |
650 |
HGG biology is the same in children as in adults! |
651 |
The brainstem is a frequent location of childhood HGG. |
652 |
Infants (<3 yrs) with HGG have a worse prognosis than older child |
653 |
Management of high grade glioma in children |
654 |
Paediatric high grade glioma: Background |
655 |
Paediatric brain tumours |
656 |
High Grade Glioma in children |
657 |
Pathology |
658 |
Slide Number 11 |
659 |
Epidemiology |
660 |
Clinical Presentation- non-brainstem HGG |
661 |
Diagnosis: HGG |
662 |
Brainstem Glioma in Children |
663 |
Brainstem tumors |
664 |
Diffuse Intrinsic Pontine glioma (DIPG) |
665 |
Slide Number 18 |
666 |
DIPG: Clinical Presentation |
667 |
DIPG: Clinical Presentation |
668 |
Diagnosis: DIPG |
669 |
DIPG: To biopsy or not to biopsy? |
670 |
Ethics of Biopsy? |
671 |
Slide Number 24 |
672 |
Slide Number 25 |
673 |
Diffuse Intrinsic Pontine Glioma (DIPG) |
674 |
What is the standard of care for DIPG? |
675 |
Slide Number 28 |
676 |
HFRT for DIPG |
677 |
Hypofractionated Radiotherapy in DIPG? |
678 |
Slide Number 31 |
679 |
Slide Number 32 |
680 |
Slide Number 33 |
681 |
Slide Number 34 |
682 |
Slide Number 35 |
683 |
Why have we failed? |
684 |
Why have we failed? |
685 |
Slide Number 38 |
686 |
Slide Number 39 |
687 |
Slide Number 40 |
688 |
Slide Number 41 |
689 |
Why have we failed? |
690 |
Slide Number 43 |
691 |
Slide Number 44 |
692 |
Slide Number 45 |
693 |
Pre-clinical Models |
694 |
Rapid Preclinical Development of a Targeted Therapy Combination for DIPG |
695 |
Preclinical Consortium |
696 |
Slide Number 49 |
697 |
Slide Number 50 |
698 |
Slide Number 51 |
699 |
Slide Number 52 |
700 |
Slide Number 53 |
701 |
Slide Number 54 |
702 |
Slide Number 55 |
703 |
Why have we failed? |
704 |
Slide Number 57 |
705 |
DIPG Specific Targets! |
706 |
Slide Number 59 |
707 |
Why have we failed? |
708 |
Poor Drug Delivery |
709 |
Slide Number 62 |
710 |
CED DIPG Trials |
711 |
Slide Number 64 |
712 |
Slide Number 65 |
713 |
Slide Number 66 |
714 |
Slide Number 67 |
715 |
Intra-arterial Clinical Trials |
716 |
Nanoparticles |
717 |
Intranasal Delivery |
718 |
Biopsy directed therapies |
719 |
BIOMEDE Study |
720 |
Three major targets selected |
721 |
Slide Number 74 |
722 |
Three drugs selected |
723 |
Slide Number 76 |
724 |
Slide Number 77 |
725 |
Diagnostic workout |
726 |
Prognostic impact of histone mutations |
727 |
Slide Number 80 |
728 |
Current standard treatments & outcomes for pHGG |
729 |
Surgery |
730 |
Surgery |
731 |
Slide Number 84 |
732 |
Slide Number 85 |
733 |
Slide Number 86 |
734 |
Target volumes |
735 |
Slide Number 88 |
736 |
Slide Number 89 |
737 |
Slide Number 90 |
738 |
Slide Number 91 |
739 |
Slide Number 92 |
740 |
Chemotherapy and autologous stem cell rescue |
741 |
Chemotherapy and autologous stem cell rescue |
742 |
Chemotherapy and autologous stem cell rescue |
743 |
Infant HGG (< 3 years) can be spared from radiation therapy with a good outcome |
744 |
Slide Number 97 |
745 |
Slide Number 98 |
746 |
What is the standard Rx in pHGG? |
747 |
Adult Glioblastoma- 1st Line therapy |
748 |
Slide Number 101 |
749 |
EFS and OS rates of 90 HGG patients |
750 |
Slide Number 103 |
751 |
Slide Number 104 |
752 |
Paediatric high grade glioma: are they the same as HGG in adults? |
753 |
Slide Number 106 |
754 |
Slide Number 107 |
755 |
Slide Number 108 |
756 |
Slide Number 109 |
757 |
Identification of somatic H3F3A mutations |
758 |
Slide Number 111 |
759 |
Slide Number 112 |
760 |
Tumour location & Shared Targets? |
761 |
Paediatric and Adult HGGSimilarities and Differences |
762 |
Define a common backbone! |
763 |
Recent Trial in HGG |
764 |
Slide Number 117 |
765 |
Slide Number 118 |
766 |
Participating countries in this study |
767 |
Slide Number 120 |
768 |
Slide Number 121 |
769 |
Slide Number 122 |
770 |
Slide Number 123 |
771 |
Slide Number 124 |
772 |
Slide Number 125 |
773 |
MAPK Pathway Inhibitors |
774 |
SELECTIVE BRAF INHIBITORS |
775 |
Slide Number 128 |
776 |
Slide Number 129 |
777 |
Slide Number 130 |
778 |
Slide Number 131 |
779 |
BRAFV600 Mutations –pHGG Target? |
780 |
BRAF PATHWAY |
781 |
Brain Tumour Delivery with BRAFi?Worked in Melanoma Brain Mets! |
782 |
Slide Number 135 |
783 |
Slide Number 136 |
784 |
Slide Number 137 |
785 |
Slide Number 138 |
786 |
Slide Number 139 |
787 |
Slide Number 140 |
788 |
Slide Number 141 |
789 |
Paediatric high grade glioma: conclusions |
790 |
Conclusions |
791 |
Conclusions |
792 |
L19_Medulloblastoma in children_UR(final) |
793 |
Slide Number 1 |
793 |
Slide Number 2 |
794 |
Slide Number 3 |
795 |
Medulloblastoma |
796 |
Slide Number 5 |
797 |
Slide Number 6 |
798 |
Slide Number 7 |
799 |
Slide Number 8 |
800 |
Slide Number 9 |
801 |
Slide Number 10 |
802 |
Slide Number 11 |
803 |
SIOP PNET 4 : survival by histologic subtypes |
804 |
Slide Number 13 |
805 |
Histology + molecular variables |
806 |
Medulloblastoma: the (near) future |
807 |
Slide Number 16 |
808 |
Slide Number 17 |
809 |
Post-operative treatments |
810 |
Late toxicity related to CSI |
811 |
How can we reduce the risks associated with CSI? |
812 |
Slide Number 21 |
813 |
Slide Number 22 |
814 |
Slide Number 23 |
815 |
Slide Number 24 |
816 |
Standard risk childhood MB |
817 |
Slide Number 26 |
818 |
Slide Number 27 |
819 |
The posterior fossa boost |
820 |
CTV for the posterior fossa boost |
821 |
The posterior fossa boost |
822 |
Radiotherapy technique |
823 |
Whole PF: Lateral opposed → 3D CRT |
824 |
Whole PF: Lateral opposed → IMRT |
825 |
Whole PF vs tumour bed boost: ongoing trials |
826 |
Whole PF vs tumour bed |
827 |
Reduced volume tumour bed boost |
828 |
Limit volume boost (ACNS0331) |
829 |
Slide Number 38 |
830 |
Slide Number 39 |
831 |
Slide Number 40 |
832 |
Slide Number 41 |
833 |
Slide Number 42 |
834 |
Medulloblastoma |
835 |
Slide Number 44 |
836 |
Slide Number 45 |
837 |
Slide Number 46 |
838 |
Slide Number 47 |
839 |
Radiotherapy dose |
840 |
Long-term complications of treatment |
841 |
Slide Number 50 |
842 |
Slide Number 51 |
843 |
Late toxicity related to CSI |
844 |
How can we reduce the risks associated with CSI? |
845 |
IMRT for the spine field |
846 |
Concluding remarks |
847 |
L20_Management of Low Grade Glioma in children_DH 2015 |
848 |
Management of low grade glioma in children |
848 |
Pathology of LGG in adults and children is usually the same! |
849 |
Most common location for childhood LGG is cerebral hemisphere |
850 |
LGG in children <1 year has a better prognosis! |
851 |
Malignant transformation rate in childhood LGG is ~30%. |
852 |
Low Grade Glioma in Children |
853 |
Low Grade Glioma in Children |
854 |
Slide Number 8 |
855 |
Pilocytic astrocytomas |
856 |
Juvenile Pilocytic Astrocytoma |
857 |
Low Grade Glioma in Children |
858 |
Low Grade Glioma in Children |
859 |
Aetiology of Childhood LGG |
860 |
Optic Pathway Glioma |
861 |
Slide Number 15 |
862 |
MAPK Pathway |
863 |
Slide Number 17 |
864 |
MAPK activation in PA |
865 |
Slide Number 19 |
866 |
Slide Number 20 |
867 |
Slide Number 21 |
868 |
Slide Number 22 |
869 |
Slide Number 23 |
870 |
Slide Number 24 |
871 |
Slide Number 25 |
872 |
Slide Number 26 |
873 |
Slide Number 27 |
874 |
Slide Number 28 |
875 |
Slide Number 29 |
876 |
Slide Number 30 |
877 |
Slide Number 31 |
878 |
Slide Number 32 |
879 |
Slide Number 33 |
880 |
Slide Number 34 |
881 |
Slide Number 35 |
882 |
Slide Number 36 |
883 |
Slide Number 37 |
884 |
Slide Number 38 |
885 |
Slide Number 39 |
886 |
Slide Number 40 |
887 |
Slide Number 41 |
888 |
Slide Number 42 |
889 |
Slide Number 43 |
890 |
Slide Number 44 |
891 |
Slide Number 45 |
892 |
Slide Number 46 |
893 |
Slide Number 47 |
894 |
Low Grade Glioma in Children |
895 |
Slide Number 49 |
896 |
Slide Number 50 |
897 |
Slide Number 51 |
898 |
Slide Number 52 |
899 |
Slide Number 53 |
900 |
Slide Number 54 |
901 |
Slide Number 55 |
902 |
Slide Number 56 |
903 |
Slide Number 57 |
904 |
Slide Number 58 |
905 |
Slide Number 59 |
906 |
Slide Number 60 |
907 |
Slide Number 61 |
908 |
Slide Number 62 |
909 |
Slide Number 63 |
910 |
FUTURE management of LGG |
911 |
Slide Number 65 |
912 |
Slide Number 66 |
913 |
Slide Number 67 |
914 |
Slide Number 68 |
915 |
Strategisches Konzept |
916 |
Slide Number 70 |
917 |
Warum molekulare Biomarker? |
918 |
Warum molekulare Biomarker? |
919 |
Slide Number 73 |
920 |
Slide Number 74 |
921 |
Visual acuity (VA) as the primary measure |
922 |
Visual indications to treatment |
923 |
Vision-related severe symptoms (WHO def) |
924 |
Targeting BRAF and MEK pathway in LGG |
925 |
Outline |
926 |
BRAF abnormalities – hallmark signature for PA |
927 |
Slide Number 81 |
928 |
BRAF driven mouse model of PA |
929 |
Sorafenib as a MEK inhibitor |
930 |
Sorafenib |
931 |
Sorafenib – in vitro inhibitory concentrations |
932 |
Slide Number 86 |
933 |
Slide Number 87 |
934 |
Slide Number 88 |
935 |
Slide Number 90 |
936 |
Slide Number 91 |
937 |
Slide Number 92 |
938 |
RAF inhibitors prime wild-type RAF to activate MAPK signaling and enhance tumor growth |
939 |
Slide Number 94 |
940 |
A Phase 1 Study of AZD6244 in Children with Recurrent or Refractory Low Grade Gliomas: A Pediatric Brain Tumor Consortium Report. |
942 |
A Phase 1 Study of AZD6244 in Children with Recurrent or Refractory Low Grade Gliomas: A Pediatric Brain Tumor Consortium Report. |
943 |
Slide Number 98 |
944 |
AZD 6244 - RESPONSE |
945 |
Largest Percentage Reduction in Tumor Volume from Baseline by BRAF Aberration (Min Tumor Volume/Baseline Volume) |
946 |
Slide Number 101 |
947 |
PBTC29 – Phase II study |
948 |
Phase 1 study of dabrafenib in pediatric patients with relapsed or refractory BRAFV600-mutant high-grade gliomas, low-grade gliomas, histiocytosis, and other solid tumors |
949 |
Dabrafenib Activity in Adults With BRAFV600-mutant Melanoma |
950 |
Dabrafenib Activity in Brain Metastases |
951 |
BRAFV600 Mutations in Pediatric Tumors |
952 |
Study Objectives |
953 |
Slide Number 108 |
954 |
Slide Number 109 |
955 |
Methods |
956 |
Baseline Patient Characteristics |
957 |
Results |
958 |
Adverse Events |
959 |
Investigator-assessed Best Confirmed Responsea by Tumor Type |
960 |
Summary |
961 |
Conclusions |
962 |
Conclusions |
963 |
L21_Clinical Trials Adult Medulloblastoma Darren Hargrave 2015 |
964 |
Adult Medulloblastoma |
964 |
Have you ever treated an adult MB patient? |
965 |
Adult Medulloblastoma: Data? |
966 |
Adult data needed for Clinical Trial Design? |
967 |
Incidence of adult medulloblastoma? |
968 |
Risk Groups |
969 |
What would be your standard Rx for adult SR-MB |
970 |
Slide Number 8 |
971 |
Slide Number 9 |
972 |
Slide Number 10 |
973 |
Outcomes? |
974 |
Outcomes? |
975 |
Adult Medulloblastoma: Biology/ Novel Rx? |
976 |
Slide Number 14 |
977 |
Slide Number 15 |
978 |
Slide Number 16 |
979 |
Slide Number 17 |
980 |
Slide Number 18 |
981 |
Gorlin Syndrome |
982 |
The SHH signalling pathway |
983 |
Slide Number 21 |
984 |
Sonic Hedgehog & Corn Lillies |
985 |
Slide Number 23 |
986 |
Slide Number 24 |
987 |
The Hedgehog (Hh) Pathway |
988 |
Slide Number 26 |
989 |
LDE225 induced tumor regression is associated with Gli1 suppression in tumor |
990 |
Slide Number 28 |
991 |
Slide Number 29 |
992 |
LDE225: responses in medulloblastoma |
993 |
Phase I/II: Study Design |
994 |
Phase I: Complete Tumor Responses in MB |
995 |
The 5-Gene Hh Signature |
996 |
Phase I: Best Overall Tumor Response and Correlation With 5-Gene Hh Signature in MB |
997 |
Clinical Trial Design Options? |
998 |
Which of the following trials do you prefer? |
999 |
Discussion on which trial is best/ feasible? |
1000 |
Slide Number 38 |
1001 |
Randomized Phase II C2201 Study DesignHh-pathway activated relapsed MB in children and adults |
1002 |
Conclusions |
1003 |
L22_ESTRO course_Management of Skull base tumors_Damien Charles Weber__140915 |
1004 |
L23_benign brain tumours_MB |
1051 |
Slide Number 1 |
1051 |
Management of benign brain tumours |
1052 |
Management of benign brain tumours |
1053 |
Management options in benign brain tumours |
1054 |
Management options in benign brain tumours |
1055 |
Management options in benign brain tumours |
1056 |
Dose fractionation in benign brain tumours |
1057 |
Management of benign brain tumours |
1058 |
Management of benign brain tumours |
1059 |
Slide Number 10 |
1060 |
Slide Number 11 |
1061 |
Management options in pituitary adenoma |
1062 |
Management options in pituitary adenoma |
1063 |
Radiation for pituitary adenoma |
1064 |
Radiation for pituitary adenoma |
1065 |
Radiation for pituitary adenoma |
1066 |
Residual pituitary adenoma |
1067 |
Residual pituitary adenoma |
1068 |
Radiation for pituitary adenoma |
1069 |
Radiation for pituitary adenoma |
1070 |
Management options in pituitary adenoma |
1071 |
Management options in pituitary adenoma |
1072 |
Endpoints in the evaluation of irradiation |
1073 |
Comparison of high precision techniques |
1074 |
Conventional radiotherapy |
1075 |
Fractionated stereotactic radiotherapy (SCRT) |
1076 |
Conventional & stereotactic radiotherapy |
1077 |
Gamma knife radiosurgery in nonfunctioning p.a. |
1078 |
Endpoints in the evaluation of irradiation |
1079 |
Endpoints in the evaluation of irradiation |
1080 |
Slide Number 31 |
1081 |
Conventional radiotherapy for acromegaly |
1082 |
GK radiosurgery for acromegaly |
1083 |
Endpoints in the evaluation of irradiation |
1084 |
Endpoints in the evaluation of irradiation |
1085 |
Slide Number 36 |
1086 |
Slide Number 37 |
1087 |
Slide Number 38 |
1088 |
Slide Number 39 |
1089 |
Slide Number 40 |
1090 |
Slide Number 41 |
1091 |
Slide Number 42 |
1092 |
Slide Number 43 |
1093 |
Slide Number 44 |
1094 |
Endpoints in the evaluation of irradiation |
1095 |
Slide Number 46 |
1096 |
Slide Number 47 |
1097 |
Pituitary adenoma |
1098 |
Pituitary adenoma |
1099 |
Pituitary adenoma |
1100 |
Slide Number 51 |
1101 |
Management of benign brain tumours |
1102 |
Slide Number 53 |
1103 |
Management options in vestibular schwannoma |
1104 |
Management options in vestibular schwannoma |
1105 |
Surveillance |
1106 |
Surveillance |
1107 |
Surveillance |
1108 |
Surveillance |
1109 |
Management options in vestibular schwannoma |
1110 |
Fractionation in high precision radiotherapy |
1111 |
Fractionation in high precision radiotherapy |
1112 |
Stereotactic RT for acoustic neuroma |
1113 |
Stereotactic RT for acoustic neuroma |
1114 |
Stereotactic RT for acoustic neuroma |
1115 |
Stereotactic RT for acoustic neuroma |
1116 |
Fractionation in high precision radiotherapy |
1117 |
Kapoor et al 2010, Int J Rad Oncol Biol Phys, Johns Hopkins experience |
1118 |
Management of benign brain tumours |
1119 |
Management options in craniopharyngioma |
1120 |
Management options in craniopharyngioma |
1121 |
Surgery for craniopharyngioma |
1122 |
Craniopharyngioma management |
1123 |
Craniopharyngioma management |
1124 |
Craniopharyngioma management |
1125 |
Craniopharyngioma management |
1126 |
Craniopharyngioma management |
1127 |
Craniopharyngioma management |
1128 |
Radiotherapy for craniopharyngioma |
1129 |
Conventional radiotherapy for craniopharyngioma |
1130 |
High precision radiotherapy for craniopharyngioma |
1131 |
Tumour control following radiotherapy |
1132 |
Slide Number 83 |
1133 |
L24_Brada brain mets_MB |
1134 |
Slide Number 1 |
1134 |
Oncological management options |
1135 |
Oncological management options |
1136 |
Oncological management options |
1137 |
Oncological management options |
1138 |
Radiotherapy in the treatment of brain metastases |
1139 |
Radiotherapy in the treatment of brain metastases |
1140 |
Radiotherapy options |
1141 |
Radiotherapy options |
1142 |
Slide Number 10 |
1143 |
Radiotherapy options |
1144 |
Radiotherapy options |
1145 |
Radiotherapy options |
1146 |
Radiotherapy options |
1147 |
Radiotherapy options |
1148 |
Radiotherapy options |
1149 |
Comparison of whole brain and partial brain RT |
1150 |
Partial brain RT after surgery for solitary brain metastases |
1151 |
Partial brain RT after surgery for solitary brain metastases |
1152 |
Radiotherapy options |
1153 |
Radiotherapy options |
1154 |
Radiotherapy options |
1155 |
Radiotherapy options |
1156 |
Radiosurgery for solitary brain metastases |
1157 |
Radiotherapy in the treatment of brain metastases |
1158 |
Oncological management options |
1159 |
Oncological management options |
1160 |
Prognosis in patients with brain metastases |
1161 |
Oncological management options |
1162 |
Prognosis in patients with brain metastases |
1163 |
Oncological management options |
1164 |
Brain metastases in malignancy |
1165 |
Slide Number 33 |
1166 |
Brain metastases in malignancy |
1167 |
Oncological management options |
1168 |
Slide Number 36 |
1169 |
Radiotherapy in the treatment of brain metastases |
1170 |
Evidence base for radiotherapy in the treatment of brain metastases |
1171 |
Evidence base for radiotherapy in the treatment of brain metastases |
1172 |
Evidence base for radiotherapy in the treatment of brain metastases |
1173 |
Slide Number 41 |
1174 |
Slide Number 42 |
1175 |
Evidence base for radiotherapy in the treatment of brain metastases |
1176 |
Radiosurgery for “solitary” brain metastases |
1177 |
Radiosurgery for solitary brain metastases |
1178 |
Radiosurgery for solitary brain metastases |
1179 |
Evidence base for radiotherapy in the treatment of brain metastases |
1180 |
Whole brain radiotherapy following surgery or radiosurgery |
1181 |
Whole brain radiotherapy following surgery or radiosurgery |
1182 |
Whole brain radiotherapy following surgery or radiosurgery |
1183 |
Whole brain radiotherapy following surgery or radiosurgery |
1184 |
Whole brain radiotherapy following surgery or radiosurgery |
1185 |
Whole brain radiotherapy following radiosurgery |
1186 |
Whole brain radiotherapy following radiosurgery |
1187 |
Whole brain radiotherapy following radiosurgery |
1188 |
Whole brain radiotherapy following radiosurgery |
1189 |
Evidence base for radiotherapy in the treatment of brain metastases |
1190 |
Evidence base for radiotherapy in the treatment of brain metastases |
1191 |
Effect of whole brain radiotherapy on survival |
1192 |
Brain metastases in malignancy |
1193 |
Evidence base for radiotherapy in the treatment of brain metastases |
1194 |
Effect of whole brain radiotherapy on survival & QOL |
1195 |
Effect of whole brain radiotherapy on survival & QOL |
1196 |
Effect of whole brain radiotherapy on survival & QOL |
1197 |
Effect of whole brain radiotherapy on survival & QOL |
1198 |
Evidence base for radiotherapy in the treatment of brain metastases |
1199 |
Evidence base for radiotherapy in the treatment of brain metastases |
1200 |
Evidence base for radiotherapy in the treatment of brain metastases |
1201 |
Evidence base for radiotherapy in the treatment of brain metastases |
1202 |
Radiosurgery for “solitary” brain metastases |
1203 |
Radiosurgery for oligometastases in the brain |
1204 |
Radiosurgery for oligometastases in the brain |
1205 |
Evidence base for radiotherapy in the treatment of brain metastases |
1206 |
Slide Number 74 |
1207 |
Stereotactic radiotherapy utilisation |
1208 |
Stereotactic radiosurgery utilisation |
1209 |
Stereotactic radiotherapy utilisation |
1210 |
Stereotactic radiosurgery utilisation |
1211 |
Stereotactic radiosurgery utilisation |
1212 |
Stereotactic radiosurgery utilisation |
1213 |
Stereotactic radiosurgery utilisation |
1214 |
Oncological management options |
1215 |
Slide Number 83 |
1216 |
Slide Number 84 |
1217 |
Systemic therapy for brain metastases |
1218 |
Oncological management options |
1219 |
Slide Number 87 |
1220 |
Evidence base for radiotherapy in the treatment of brain metastases |
1221 |
Slide Number 89 |
1222 |
Slide Number 90 |
1223 |
Slide Number 91 |
1224 |
Evidence base for radiotherapy in the treatment of brain metastases |
1225 |
Radiosurgery for synchronous brain oligometastases |
1226 |
Radiosurgery for synchronous brain oligometastases |
1227 |
Evidence base for radiotherapy in the treatment of brain metastases |
1228 |
Additional systemic therapy in NSCLC brain metastases |
1229 |
Additional systemic therapy in NSCLC brain metastases |
1230 |
Evidence base for radiotherapy in the treatment of brain metastases |
1231 |
Slide Number 99 |
1232 |
L25_ESTRO_supportive-treatment_Roth |
1233 |
Slide Number 1 |
1233 |
Slide Number 2 |
1234 |
Slide Number 3 |
1235 |
Slide Number 4 |
1236 |
Slide Number 5 |
1237 |
Slide Number 6 |
1238 |
Slide Number 7 |
1239 |
Slide Number 8 |
1240 |
Slide Number 9 |
1241 |
Slide Number 10 |
1242 |
Slide Number 11 |
1243 |
Slide Number 12 |
1244 |
Slide Number 13 |
1245 |
Slide Number 14 |
1246 |
Slide Number 15 |
1247 |
Slide Number 16 |
1248 |
Slide Number 17 |
1249 |
Slide Number 18 |
1250 |
Slide Number 19 |
1251 |
Slide Number 20 |
1252 |
Slide Number 21 |
1253 |
Slide Number 22 |
1254 |
Slide Number 23 |
1255 |
Slide Number 25 |
1256 |
Slide Number 26 |
1257 |
Slide Number 27 |
1258 |
Slide Number 29 |
1259 |
Slide Number 31 |
1260 |
Slide Number 32 |
1261 |
Slide Number 33 |
1262 |
Slide Number 34 |
1263 |
Slide Number 35 |
1264 |
Slide Number 37 |
1265 |
Slide Number 38 |
1266 |